Moreover, a computational analysis of bacteriocin products of the common probiotic Lactobacillus plantarum found that some of the plantiricin compounds may competitively inhibit binding with RdRp, RBD, and ACE2 proteins of SARS-CoV-2, indicating potential for a L. plantarum probiotic treatment for COVID-19 [203]. The gene discussed is ACE2; the disease is COVID-19.